Provided by Tiger Fintech (Singapore) Pte. Ltd.

Olema Pharmaceuticals, Inc.

4.14
-0.3100-6.97%
Volume:487.50K
Turnover:2.03M
Market Cap:307.20M
PE:-1.81
High:4.36
Open:4.36
Low:4.09
Close:4.45
Loading ...

Olema Partners With Novartis for Clinical Trial of Potential Breast Cancer Drug, Launches $250 Million Stock, Warrant Placement

MT Newswires Live
·
02 Dec 2024

BRIEF-Olema Oncology Announces New Clinical Trial Collaboration And Supply Agreement With Novartis In Frontline Metastatic Breast Cancer As Well As $250 Million Equity Private Placement

Reuters
·
02 Dec 2024

Press Release: Olema Oncology Announces New Clinical Trial Collaboration and Supply Agreement with Novartis in Frontline Metastatic Breast Cancer as well as $250 Million Equity Private Placement

Dow Jones
·
02 Dec 2024

Olema Oncology Announces New Clinical Trial Collaboration and Supply Agreement With Novartis in Frontline Metastatic Breast Cancer as Well as $250 Million Equity Private Placement

THOMSON REUTERS
·
02 Dec 2024

Olema Pharmaceuticals Inc - Well Capitalized to Fund Operations Beyond Key Milestones

THOMSON REUTERS
·
02 Dec 2024

Olema Oncology to Present New Data Combining Palazestrant with Ribociclib at the San Antonio Breast Cancer Symposium

GlobeNewswire
·
26 Nov 2024

Press Release: Ascentage Pharma Appoints Ms. Marina S. Bozilenko and Dr. Debra Yu as Independent Non-Executive Directors

Dow Jones
·
25 Nov 2024

Optimistic Buy Rating for Olema Pharmaceuticals Driven by Promising Developments with Palazestrant and Novartis Collaboration

TIPRANKS
·
22 Nov 2024

J.P. Morgan Keeps Their Buy Rating on Olema Pharmaceuticals (OLMA)

TIPRANKS
·
21 Nov 2024

U.S. RESEARCH ROUNDUP- Apellis Pharmaceuticals, Energizer Holdings, Walmart

Reuters
·
20 Nov 2024

Olema Pharmaceuticals Price Target Maintained With a $30.00/Share by HC Wainwright & Co.

Dow Jones
·
14 Nov 2024

TD Cowen Sticks to Its Buy Rating for Olema Pharmaceuticals (OLMA)

TIPRANKS
·
13 Nov 2024

Olema Pharmaceuticals Inc reports results for the quarter ended September 30 - Earnings Summary

Reuters
·
13 Nov 2024

Olema Pharmaceuticals Q3 EPS $(0.60) Misses $(0.57) Estimate

Benzinga
·
13 Nov 2024

Olema Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate Update

THOMSON REUTERS
·
13 Nov 2024

Olema Pharmaceuticals Inc expected to post a loss of 58 cents a share - Earnings Preview

Reuters
·
06 Nov 2024